![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
We report on clinical outcomes in patients with oligometastatic uterine cancer treated with stereotactic body radiation therapy (SBRT). Twenty-seven patients with 61 lesions were treated with SBRT. Median follow-up was 16.9 months. Local control was achieved in 49/61 (80.3%) lesions. One-year local-progression-free survival and overall survival were 75.9% and 65.4%. Lesions with favorable response were smaller than lesions with unfavorable response (p = .007). Liver lesions were less likely to achieve favorable response (p = .0128). There were no grade 3 or 4 events. Treatment with SBRT can provide excellent local control in oligometastatic uterine cancer with minimal toxicity.
Disclosure statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
Author contributions
Conception and design: Abhinav V. Reddy, Matthew N. Mills, Leonid B. Reshko, Charles R. Kersh. Data analysis and interpretation: Abhinav V. Reddy, Matthew N. Mills, Leonid B. Reshko, K. Martin Richardson. Manuscript writing: Abhinav V. Reddy, Matthew N. Mills. Final approval of manuscript: Abhinav V. Reddy, Matthew N. Mills, Leonid B. Reshko, Charles R. Kersh.